AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association
about
Aspirin in primary prevention of cardiovascular disease and cancer: a systematic review of the balance of evidence from reviews of randomized trialsReview of guidelines on primary prevention of cardiovascular disease with aspirin: how much evidence is needed to turn a tanker?Automated telephone communication systems for preventive healthcare and management of long-term conditionsMultiple risk factor interventions for primary prevention of coronary heart diseaseMultiple risk factor interventions for primary prevention of coronary heart diseaseAssociation between carbohydrate intake and serum lipidsObesity among chronically homeless adults: is it a problem?Effects of some common food constituents on cardiovascular diseaseAspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trialsAir pollution and heart rate variability: effect modification by chronic lead exposureLow-carbohydrate and high-fat intake among adult patients with poorly controlled type 2 diabetes mellitusWhy combine diet and physical activity in the same international research society?Policy and environmental indicators for heart disease and stroke prevention: data sources in two states.Underutilization of aspirin persists in US ambulatory care for the secondary and primary prevention of cardiovascular disease.Adherence to heart-healthy behaviors in a sample of the U.S. population.Aspirin for primary prevention of cardiovascular diseaseYou're only as old as your arteries: translational strategies for preserving vascular endothelial function with agingEffects of Exercise Training on Cardiorespiratory Fitness and Biomarkers of Cardiometabolic Health: A Systematic Review and Meta-Analysis of Randomized Controlled TrialsEsomeprazole and aspirin fixed combination for the prevention of cardiovascular eventsThe clinical significance of antiphospholipid antibodies in systemic lupus erythematosusEffect of Flavonoids on Oxidative Stress and Inflammation in Adults at Risk of Cardiovascular Disease: A Systematic ReviewPrimary prevention of coronary heart disease in the elderlyTreatment of metabolic syndromeEpidemiological modelling of routine use of low dose aspirin for the primary prevention of coronary heart disease and stroke in those aged > or =70Aspirin under fire: aspirin use in the primary prevention of coronary heart diseaseBalancing the gastrointestinal benefits and risks of nonselective NSAIDs.Diagnosis and management of the metabolic syndrome in obesityDesign of the Dialysis Access Consortium (DAC) Clopidogrel Prevention of Early AV Fistula Thrombosis TrialThe prevalence of risk factors for gastrointestinal complications and use of gastroprotection among persons hospitalized for cardiovascular diseaseReview article: gastrointestinal bleeding with low-dose aspirin - what's the risk?Implementation of case management to reduce cardiovascular disease risk in the Stanford and San Mateo Heart to Heart randomized controlled trial: study protocol and baseline characteristicsPrimer: managing NSAID-induced ulcer complications--balancing gastrointestinal and cardiovascular risksDose of aspirin in the treatment and prevention of cardiovascular disease: current and future directionsFamily history of heart disease and cardiovascular disease risk-reducing behaviorsAntiplatelet therapy in populations at high risk of atherothrombosisUnderuse of American College of Cardiology/American Heart Association Guidelines in hemodialysis patientsUsing a summary measure for multiple quality indicators in primary care: the Summary QUality InDex (SQUID)Cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxibThe David Y. Graham lecture: use of nonsteroidal antiinflammatory drugs in a COX-2 restricted environmentUse of aspirin for primary and secondary prevention of cardiovascular disease in diabetic patients in an ambulatory care setting in Spain
P2860
Q21132402-27E6F65D-7858-4255-87D3-B77CE4E899B2Q22241777-24327E83-FAA2-4424-BC09-251D30A318B4Q24202409-43D8F004-E3CB-4C4F-B8BB-7C8F6BFEFD5DQ24234642-D36A87F2-5956-4A34-88E4-473A04F48CE2Q24243941-14B0C48F-4467-464D-B3A9-764D7FF28644Q24548278-497DB8CE-E16B-4969-AE7A-2B69344B2D15Q24603253-B980C6C7-5D48-429C-B1BA-E239C9DF2413Q24605384-B9AD1BC0-C884-44A0-BBD7-A7FB09F7863DQ24645391-1995326C-82BB-412F-96BA-FD447F69E833Q24656722-4358ADFE-85A5-4DF0-A2EF-219F73B29F32Q24676853-FD26C193-8416-4485-8A9F-B1756C06FBEAQ24802331-7F93D489-8A7D-4396-BB22-4C48F3126838Q24811351-1E19B988-AD75-47FB-B6AA-174DC2BE6C3CQ24816911-AEDBFC5B-271C-441C-AF29-ACAA66F76A82Q25255529-498A5799-20E4-40CC-A013-87F73F6253D2Q26774150-3501AB28-105D-40A9-A342-5341D20A3E41Q26824357-9A4983E7-273C-459F-B969-FCB2C9888DF4Q26827245-D955A10E-B926-4923-B20D-0E0C7BD9162AQ26995752-8E3C6BE2-CD37-4CA4-88CC-720BFA88C32EQ28072610-95600650-16AF-40E1-AEB8-74B04A5A0088Q28076821-F6516D83-BE1F-4FD2-8CAC-E728BE939511Q28165739-D3054EF4-CDA1-4975-BBA3-EEE8D49EFCF8Q28168652-25C98FA6-9193-47EE-B055-21D7D52C9440Q28175859-2A56D397-154D-469B-8BA8-AB80642FAA2CQ28176243-F71D6A49-DFEA-4CC5-9713-ABF799BF30E0Q28191932-66404E1C-16CA-4E46-9432-343E1ABFCC00Q28192856-FEEA5804-8EEA-44F1-88BF-D27787D1B78CQ28193662-73A54655-8634-4337-A347-2D9DA27C5EC4Q28195971-43C2973B-7022-4BD5-BCC4-04B9DB343CC3Q28200403-F3CDCDC2-BF3D-4BD0-9663-CDF694D60FEBQ28200558-574723B9-C31B-42E8-AA5F-2BB4172E56EEQ28200571-5F404144-8A32-43E3-9A53-F9BBCBA4D107Q28200895-394F13AE-04A0-4C7A-8C03-8CE0C70E0102Q28212567-7BC83071-2FD8-414C-8D1D-A8E3B9938DFEQ28218702-224BB0C1-FF1D-49AA-8B1A-24D6E436A287Q28218895-F338AA32-AF2D-439E-810B-0E9DD6CEA7D9Q28222052-3277FD4B-21F9-4FCF-A3BE-68990C7D66F0Q28222097-F4EB8D84-DB25-4F7E-826D-B88FB8B10750Q28222253-BE4860A8-1AAF-4DB2-BF9C-52A1DC5E37C0Q28222880-DFAD5AB8-57CA-4333-9C22-82A6C20CCFF9
P2860
AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association
description
2002 nî lūn-bûn
@nan
2002 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
name
AHA Guidelines for Primary Pre ...... es. American Heart Association
@ast
AHA Guidelines for Primary Pre ...... es. American Heart Association
@en
AHA Guidelines for Primary Pre ...... es. American Heart Association
@nl
type
label
AHA Guidelines for Primary Pre ...... es. American Heart Association
@ast
AHA Guidelines for Primary Pre ...... es. American Heart Association
@en
AHA Guidelines for Primary Pre ...... es. American Heart Association
@nl
prefLabel
AHA Guidelines for Primary Pre ...... es. American Heart Association
@ast
AHA Guidelines for Primary Pre ...... es. American Heart Association
@en
AHA Guidelines for Primary Pre ...... es. American Heart Association
@nl
P2093
P50
P921
P1433
P1476
AHA Guidelines for Primary Pre ...... es. American Heart Association
@en
P2093
Barry A Franklin
Ira S Ockene
Joan M Fair
Kathryn A Taubert
Larry B Goldstein
Nancy Houston Miller
Neil J Stone
Philip Greenland
Robert H Eckel
Ronald M Lauer
P304
P356
10.1161/01.CIR.0000020190.45892.75
P407
P577
2002-07-01T00:00:00Z